Market Overview

Medidata Rave Engage Wins Scrip Award for Best Sponsor-Focused Technological Development in Clinical Trials

Share:
  • Rave Engage Named Top Technology for Sponsors at 14th Annual Scrip
    Awards
  • Medidata Wins Prestigious Industry Award for Third Consecutive Year
  • Scrip Award Celebrates Innovation and Excellence in
    Biopharmaceutical Industry

Medidata
(NASDAQ:MDSO) is pleased to announce that Rave Engage was recognized at
the 2018 Scrip Awards as the "Best Technological Development in Clinical
Trials - Tech Sponsor Focused." This marks the third consecutive Scrip
Award
win for the company.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20181130005221/en/

(Graphic: Business Wire)

(Graphic: Business Wire)

Medidata Rave Engage is an intuitive web-based application that serves
as the patient-facing interface for virtual trials and hybrid studies
that seek to reduce physical site visits. Patients remain engaged
throughout the study with what Medidata calls the "Trial Dial," which
enables sponsors to choose the right balance of site-based and virtual
visits. Through Rave Engage, sponsors and investigators improve
operational efficiency, scalability, and patient recruitment and
retention—all of which result in better data and lower trial costs.

Presented to Medidata at the 14th Annual Scrip Awards on November 28,
2018 in London, the award celebrates excellence and innovation in the
biopharmaceutical industry and a continued commitment to improving
healthcare on a global scale. A panel of judges—comprised of
independent, senior industry experts from around the world—evaluated a
record number of submissions across a wide range of categories,
announcing a shortlist of finalists earlier this year.

"Medidata Rave Engage improves the entire patient and sponsor experience
with clinical trial virtualization," said Anthony Costello, vice
president, mHealth, Medidata. "Modern clinical trials, especially
large-scale trials, need to be more efficiently run and convenient for
patients. We believe that virtual and hybrid trials, made possible by
Rave Engage and the Medidata platform, are the future of clinical
research."

Rave Engage currently powers a number of virtual studies for global
pharmaceutical and biopharmaceutical companies, including the
well-publicized aspirin study, ADAPTABLE—the largest virtual trial ever
conducted, with an enrollment target of 15,000 patients. With the Rave
Engage platform, ADAPTABLE patients are virtually enrolled, consented,
and randomized to provide their own reported outcome throughout the
study with no physical site visits.

About Medidata

Medidata is leading the digital transformation of life sciences, with
the world's most used platform for clinical development, commercial, and
real-world data. Powered by artificial intelligence and delivered by the
#1 ranked industry experts, the Intelligent Platform for Life Sciences
helps pharmaceutical, biotech, medical device companies, and academic
researchers accelerate value, minimize risk and optimize outcomes.
Medidata serves more than 1,000 customers and partners worldwide and
empowers more than 100,000 certified users every day to create hope for
millions of patients. Discover the future of life sciences: www.mdsol.com

View Comments and Join the Discussion!